Croma Pharma Gmbh

Sealife Pharma Gmbh

Ralph Hollaus

Michael Nagl

Martin Prinz

Alexander Pretsch

Christoph Wiesner

Robert Sachsenhofer

Miroslav Genov

A thiol-modified hyaluronan, wherein the thiol-modified hyaluronan comprises a plurality of modification groups with a thiol-group in the hyaluronan side-chains, wherein the modification group comprises an amino acid residue with basic side chain and a conjugated terminal naturally occurring amino-thiol as well as a sterile hydrogel composition comprising a crosslinked polymer, wherein the crosslinked polymer is an oxidation product of the thiol-modified hyaluronan and uses of the composition.

Thiol-modified hyaluronan and hydrogel comprising the crosslinked hyaluronan

A sterile hydrogel composition that includes a crosslinked polymer, wherein the crosslinked polymer is an oxidation product of a thiol-modified hyaluronan and wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of more than about 80 μmol per gram polymer, wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of less than about 280 μmol per gram polymer, and wherein the thiol-modified hyaluronan has a mean molecular weight of at least 400 kDa.

Hydrogel composition comprising a crosslinked polymer

A sterile hydrogel composition comprising a crosslinked polymer, wherein the crosslinked polymer is an oxidation product of a thiol-modified hyaluronan and wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of more than about 80 μmol per gram polymer, wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of less than about 280 μmol per gram polymer, wherein the composition has a residual thiol content of less than 20% in respect to the degree of modification of the thiol-modified hyaluronan.

Polyguanidines and methods of use thereof are described. In particular, polyguanidines of formula (I), formula (II), and formula (III) are described. The polyguanidines can be used to treat infection, such as bacterial, viral or fungal infection, and as an ex vivo microbial agent. 

Polyguanidine polymers and methods of use thereof

A method for preparing polycondensation products of guanidine, aminoguanidine or diaminoguanidine G with one or more benzyl or allyl derivatives BA according to the following reaction scheme is provided: wherein X, R, Gua, Y and Z are as defined in the specification. In the disclosed method, at least one benzyl or allyl derivative BA is subjected to a polycondensation reaction with excessive guanidine, aminoguanidine or diaminoguanidine G upon elimination of HX.

Growing community of inventors

Vienna, Austria

Ralph Hollaus